24/7 Market News Snapshot 03 July, 2025 – Clearmind Medicine Inc. Common Shares (NASDAQ:CMND)

July 3, 2025

DENVER, Colo., 03 July, 2025 (www.247marketnews.com) – (Nasdaq:CMND) are discussed in this article.
In a significant development for Clearmind Medicine Inc. (Nasdaq:CMND, FSE: CWY0), the company announced a remarkable surge in its stock price, reaching $1.317 in pre-market trading, representing a notable increase of 45.85% from the previous closing rate of $0.903. This upswing, evidenced by a trading volume of 9.89 million shares, reflects heightened investor interest, marking Clearmind as a focal point in today’s market.

Parallel to this market enthusiasm, Clearmind has achieved critical progress in its clinical research endeavors. The company received Institutional Review Board (IRB) approval for its Phase 1/2a clinical trial assessing CMND-100, an innovative, MEAI-based therapeutic solution aimed at treating Alcohol Use Disorder (AUD). This milestone is pivotal, as it paves the way for patient enrollment at a highly-regarded clinical site, positioning Clearmind at the forefront of psychedelic-derived therapeutics.

The trial will be conducted in collaboration with esteemed institutions such as Yale School of Medicine and Johns Hopkins University School of Medicine, further enhancing the trial’s credibility. Dr. David Zeltser, who leads the Emergency Medicine Department, will be overseeing the initiative, emphasizing the commitment to pioneering medical research.

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, expressed enthusiasm regarding the IRB approval, highlighting the company’s objective to provide effective treatment for AUD, which has a profound impact on countless lives globally. The trial will assess the safety, tolerability, and efficacy of CMND-100 in mitigating alcohol cravings and consumption.

As patient recruitment progresses, Clearmind Medicine is poised to make significant contributions to public health, with the potential to transform the therapeutic landscape for individuals battling alcohol use disorder. The combined success in stock performance and clinical advancements signals a promising trajectory for the company in the biotech sector.

Related news for (CMND)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.